Substantial pipeline and partnering
assets and opportunities
The Amphiphile platform precisely concentrates a variety of differentimmunogens in the lymph nodes to maximally impact the immune response, while conventional immunotherapies and vaccines are systemically distributed, thus limiting their ability to influence immunity in the body’s natural centers of immune action. The Amphiphile approach is also being used in concert with novel cellular therapies to utilize the lymph nodes to enhance the effectiveness of cell therapy and address the critical challenges these therapies face. Elicio is building a broad pipeline of candidates including cell therapy activators, immunomodulators, and vaccine candidates which all concentrate in the lymph nodes, to powerfully orchestrate anti-cancer immunity, with tremendous capital efficiency and speed. Elicio’s lead immunotherapy programs will enter initial patient studies in the first half of 2020.